Overview

A Study Lasmiditan (LY573144) in a Single Migraine Attack in Japanese Participants With Migraine

Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of lasmiditan in the acute treatment of a migraine attack in Japanese adult participants with or without aura.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Lasmiditan